Teleflex Completes Enrollment in Longer-Length Freesolve Scaffold Study

  • Teleflex completed enrollment in the BIOMAG™-LL Clinical Study evaluating 35 mm and 40 mm Freesolve™ Resorbable Magnesium Scaffolds for coronary lesions up to 38 mm.
  • The study is a premarket, prospective, international, multi-center, single-arm trial with a primary endpoint of Target Lesion Failure (TLF) rate at 12 months.
  • Clinical follow-up is scheduled at 1, 6, 12, 36, and 60 months post-procedure.
  • The study aims to expand treatment options for long coronary lesions, reducing the need for permanent implants.

Teleflex's completion of the BIOMAG™-LL Clinical Study is a strategic move to address the challenge of long coronary lesions in percutaneous coronary intervention (PCI). The study's success could position Teleflex as a leader in resorbable scaffold technology, offering an alternative to permanent implants and drug-coated balloons. This aligns with the broader industry trend towards minimally invasive and temporary solutions in interventional cardiology.

Clinical Efficacy
Whether the longer Freesolve™ Scaffolds demonstrate superior safety and effectiveness in treating longer coronary lesions compared to existing options.
Regulatory Approval
The pace at which Teleflex can secure regulatory approvals for the longer scaffold lengths, particularly in key markets.
Market Adoption
How quickly physicians adopt the longer scaffold lengths once data is available, and whether this expands Teleflex's market share in resorbable scaffold technology.